Inactive

Attachment 2: Request for Limited Sources Justification Format >SAT VHAPG Part 808.405-6 Limiting Sources Page 1 of 4 Revision: 01 Effective Date: 09/01/2024 Acquisition ID#: 36C250-25-AP-2741 LIMITED... Attachment 2: Request for Limited Sources Justification Format >SAT VHAPG Part 808.405-6 Limiting Sources Page 1 of 4 Revision: 01 Effective Date: 09/01/2024 Acquisition ID#: 36C250-25-AP-2741 LIMITED SOURCES JUSTIFICATION ORDER >SAT FAR PART 8.405-6 Acquisition Plan Action ID: 36C250-25-AP-2741 (1) Contracting Activity: Department of Veterans Affairs, Network Contracting Office 10, located at 24 Frank Lloyd Wright Drive, Ann Arbor, MI 48105 in support of VISN 10 VA Ann Arbor Healthcare System at 2215 Fuller Road, Ann Arbor, MI 48105. 2237: 506-26-1-020-0002. (2) Description of Action: This acquisition is conducted under the authority of the Multiple-Award Schedule Program (41 U.S.C. 152(3) and 40 U.S.C. 501). New requirement for the purchase of radioactive drug Lutetium Lu177 Vipivotide Tetra (PLUVICTO). Order against: FSS Contract Number: 36F79720D0180 Name of Proposed Contractor: Novartis Pharmaceuticals Corporation Street Address: 59 Route 10 City, State, Zip: East Hanover, NJ 07936 Phone: 862-390-9927 (3) Description of Supplies or Services: Nuclear Medicine is requesting procurement of radioactive drug Lutetium Lu177 Vipivotide Tetraxetan (PLUVICTO) (NDC 69488-0010-61) used for therapy treatment of metastatic castrate resistant prostate cancer from FDA approved sole source vendor Novartis Pharmaceuticals Corporation. This radioactive therapy drug is to be ordered and received by trained Nuclear Medicine staff only. Estimated period of performance: 10/01/2025 9/30/2030. (4) Identify the Authority and Supporting Rationale (see below and if applicable, a demonstration of the proposed contractor s unique qualifications to provide the required supply or service. FAR 8.405-6(a)(1)(A): An urgent and compelling need exists and following the ordering procedures would result in unacceptable delays: FAR 8.405-6(a)(1)(B): Only one source is capable of providing the supplies or services required at the level of quality required because the supplies or services are unique or highly specialized; This is currently the only product that is FDA approved. The radioactive drug Lutetium Lu177 Vipivotide Tetraxetan (PLUVICTO) is manufactured and distributed by a sole vendor due to guidelines in FDA approval. All Nuclear Medicine radioactive drug agents are unique and highly specialized. Novartis Pharmaceuticals Corporation has been contacted and they have confirmed they are the only source and they do not have distributors. FAR 8.405-6(a)(1)(C): In the interest of economy and efficiency, the new work is a logical follow-on to an original Federal Supply Schedule order provided that the original order was placed in accordance with the applicable Federal Supply Schedule ordering procedures. The original order must not have been previously issued under sole source or limited source procedures. FAR 8.405-6(b): Items peculiar to one manufacturer: A patent, copyright or proprietary data limits competition. The proprietary data is: These are direct replacements parts/components for existing equipment. The material/service must be compatible in all aspects (form, fit and function) with existing systems presently installed/performing. (5) Describe Why You Believe the Order Represents the Best Value consistent with FAR 8.404(d) to aid the contracting officer in making this best value determination: Novartis Pharmaceuticals Corporation is the first and only FDA approved commercial manufacture of Lutetium Lu177 Vipivotide Tetraxetan (PLUVICTO) for metastatic castrate resistant prostate cancer binding to PSMA11 receptor cells for radioactive therapy. There is no generic form or other manufacturer. Products are on a NAC contract and therefore the pricing has already been deemed fair and reasonable. A price reduction will be requested IAW FAR 8.405-4. (6) Describe the Market Research Conducted among schedule holders and the results or a statement of the reason market research was not conducted. VetCert was queried with NAICS 325412 and 132 concerns were found. DSBS search using NAICS 325412 and keyword Pluvicto resulted in 0 concerns. Novartis Pharmaceuticals Corporation is the manufacturer and the only vendor with these items on their NAC contract 36F79720D0180. They have confirmed that they have no distributors. The VA Rule of Two cannot be met, nor can the SBA Rule of Two. Items are manufactured in Italy (a TAA/WTO country). Because this is a national contract, any BAA/TAA issues regarding the items on contract and use of the contract were addressed at time of award and any subsequent delivery orders would thereby be covered as a result. Therefore, the Contracting Officer believes that placing an order against this contract would be in line with any BAA requirements and does not require any further action. Recommend FSS Sole Source to Novartis Pharmaceuticals Corporation. (7) Any Other Facts Supporting the Justification: There are no other facts supporting the justification. (8) A Statement of the Actions, if any, the agency may take to remove or overcome any barriers that led to the restricted consideration before any subsequent acquisition for the supplies or services is made: Should a requisition of this nature recur, the market will be surveyed.